Alfonso Quintas Cardama Tcr2 Therapeutics Inc. (TCRR) insider trading activity

Alfonso Quintas Cardama is Chief Medical Officer of TCR2 THERAPEUTICS INC.. Currently has a direct ownership of 0 shares of TCRR, which is worth approximately $0. The most recent transaction as insider was on Jun 01, 2023, when has been sold 109,459 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Alfonso Quintas Cardama Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 01 2023	SELL Sale (or disposition) back to the issuer	-	109,459 Reduced 100.0%	0 Common Stock
Dec 13 2022	SELL Open market or private sale	$5,037 $1.06 p/Share	4,752 Reduced 4.16%	109,459 Common Stock
Dec 12 2022	SELL Open market or private sale	$5,044 $1.1 p/Share	4,586 Reduced 3.86%	114,211 Common Stock
Dec 09 2022	SELL Open market or private sale	$5,040 $1.13 p/Share	4,461 Reduced 3.62%	118,797 Common Stock
Dec 08 2022	SELL Open market or private sale	$5,057 $1.26 p/Share	4,014 Reduced 3.15%	123,258 Common Stock
Dec 07 2022	SELL Open market or private sale	$5,027 $1.28 p/Share	3,928 Reduced 2.99%	127,272 Common Stock
Dec 06 2022	SELL Open market or private sale	$5,024 $1.33 p/Share	3,778 Reduced 2.8%	131,200 Common Stock
Dec 05 2022	SELL Open market or private sale	$5,049 $1.37 p/Share	3,686 Reduced 2.66%	134,978 Common Stock
Dec 02 2022	SELL Open market or private sale	$5,054 $1.39 p/Share	3,636 Reduced 2.56%	138,664 Common Stock
Dec 01 2022	BUY Exercise of conversion of derivative security	-	95,385 Added 40.13%	142,300 Common Stock
Dec 09 2021	BUY Exercise of conversion of derivative security	$31,820 $0.74 p/Share	43,000 Added 47.82%	46,915 Common Stock
Aug 31 2021	BUY Grant, award, or other acquisition	$2,339 $14.26 p/Share	164 Added 4.02%	3,915 Common Stock
Feb 28 2021	BUY Grant, award, or other acquisition	$11,413 $16.12 p/Share	708 Added 15.88%	3,751 Common Stock
Aug 31 2020	BUY Grant, award, or other acquisition	$11,292 $10.1 p/Share	1,118 Added 26.87%	3,043 Common Stock

Also insider at

FHTX

Foghorn Therapeutics Inc. Healthcare

Chief Medical Officer

AQC